Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Sangamo Therapeutics Stock Quote

Sangamo Therapeutics (NASDAQ: SGMO)

Price as of October 4, 2023, 4:00 p.m. ET

You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Sangamo Therapeutics Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
SGMO -88.04% -96.14% -47.85% -96%
S&P +14.98% +45.76% +7.83% +182%

Sangamo Therapeutics Company Info

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA.

News & Analysis

The Fool has written over 100 articles on Sangamo Therapeutics.


Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.